FREMONT, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ:ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that it has started shipping IQ8™ Microinverters to support newer, high-powered solar modules in select countries throughout Europe, including France, Germany, Spain, Bulgaria, Estonia, Slovakia, and Croatia. IQ8X™ Microinverters are available for customers in France, Germany, and Spain and ...

AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the upcoming Annual Meeting of The Menopause Society being held on September 10-14, 2024 in Chicago, IL. Details on the presentation can be found below. Poster:Application of Deep Neural Network-Based Algorithm to Provide Additional Information in the Asse ...

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Ixo-vec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD. "The RMAT designation is based on the clinical data from I ...

Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that it has received the official minutes from its meeting with the U.S. Food and Drug Administration ...

NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CoreCard Corporation (NYSE:CCRD) ("CoreCard" or the "Company"), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended June 30, 2024. "Overall revenue of $13.8 million in the second quarter was in-line with our expectations," said Leland Strange, CEO of CoreCard. "We continue to see encouraging results from the ongoing i ...

文章核心观点 - 南方州银行控股公司(Southern States Bancshares, Inc.)完成收购CBB Bancorp(Century Bank的控股公司) [1][2][3] - 此次收购增强了南方州银行在佐治亚州特别是亚特兰大大都市区的业务布局 [2] - 收购完成后,南方州银行将成为东南地区一流的社区银行,在阿拉巴马州和佐治亚州拥有15家全服务网点和2家贷款生产办事处 [2] 根据相关目录分别进行总结 交易概况 - 南方州银行控股公司完成收购CBB Bancorp,CBB Bancorp已并入南方州银行控股公司,Century Bank也并入南方州银行 [1] - 原CBB Bancorp股东可选择获得1.550股南方州银行普通股或45.63美元现金(最多10%的股份可获得现金对价) [3] 交易背景和目的 - 此次收购增强了南方州银行在佐治亚州特别是亚特兰大大都市区的业务布局 [2] - 收购完成后,南方州银行将成为东南地区一流的社区银行 [2] 交易对双方的影响 - 南方州银行期望此次交易能带来协同效应和其他预期收益 [6][7] - 但也面临一些风险和不确定性,如业务整合、客户和员工关系维护等 [6][7]

MURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has entered into a definitive agreement to be acquired by investment funds affiliated with TowerBrook Capital Partners and Clayton, Dubilier & Rice ("CD&R"), in an all-cash transaction with an enterprise value of approximately $8.9 billion. An investm ...

文章核心观点 - 公司的主要产品acoramidis在ATTR-CM患者中显示出显著的疗效,包括降低死亡率、住院率和改善生活质量等 [5][6] - 公司正在积极推进多个III期临床试验的全面入组,包括acoramidis、encaleret、BBP-418和infigratinib等,预计2025年将有多个产品获得关键性试验结果 [3][4][6] - 公司通过最近的融资活动,现金储备充足,为后续产品商业化和管线推进提供了有力支持 [7] 财务表现 - 公司Q2营收为2.168百万美元,较上年同期增长32% [8][9][10] - 运营成本和费用同比增加30百万美元,主要用于支持商业化准备和管线推进 [11][12][13] - 其他收益大幅增加,主要来自于子公司脱离合并的收益 [18][19][20] - 归属于普通股东的净亏损同比大幅收窄 [21][22] 管线进展 Acoramidis (ATTR-CM) - 在国际淀粉样蛋白研讨会和欧洲心力衰竭学会大会上公布了多项积极的临床数据分析结果 [5][6] - 包括显著降低复合终点事件风险、改善生命质量等 [5][6] - 公司计划今年内启动预防性试验ACT-EARLY [6] Encaleret (ADH1) - III期CALIBRATE试验正在入组,预计2025年公布关键结果 [4] BBP-418 (LGMD2I/R9) - III期FORTIFY试验入组进度超预期,计划进行中期分析 [4][6] - 获得罕见儿童疾病指定,有望获得优先审评券 [6] Infigratinib (Achondroplasia/Hypochondroplasia) - II期PROPEL 2试验Cohort 5数据显示显著提高年身高速度和改善身材比例 [6] - 获得快速通道和罕见儿童疾病指定,有望获得优先审评券 [6] - 启动观察性前导试验ACCEL,为III期试验铺平道路 [6]

ATCHISON, Kan., Aug. 01, 2024 (GLOBE NEWSWIRE) -- MGP Ingredients, Inc. (NASDAQ:MGPI), a leading provider of branded and distilled spirits as well as food ingredient solutions, today announced that its board of directors has declared a quarterly dividend of $0.12 cents per share of common stock. The dividend is payable on August 30, 2024 to stockholders of record as of August 16, 2024. About MGP Ingredients, Inc.MGP Ingredients, Inc. (NASDAQ:MGPI) is a leading producer of premium branded and distilled spiri ...

Record second quarter revenues of $3.0 billion, up 6.8% compared to second quarter 2023 Operating income of $189 million, up 21.2% compared to second quarter 2023 Net earnings of $173 million or $4.38 diluted earnings per share Delivered Virginia-class submarine New Jersey (SSN 796) Delivered amphibious transport dock Richard M. McCool Jr. (LPD 29) Company reaffirms previously issued shipbuilding guidance1 Company raises the Mission Technologies revenue guidance range1 Company reaffirms previously issued fr ...